IP Library Granted Patent US 11,472,832
Granted Patent B2
US 11,472,832 · App. 16/449,131 · Granted Oct 18, 2022

Withanolides useful for the treatment of neurodegenerative diseases

Inventors: Anthony A. Shaw (Vancouver, CA); Jean-Pierre Julien (Quebec, CA); Agnes H. Chan (Vancouver, CA)
Assignees: ARNA Therapeutics Inc.; Universite Laval
C07J71/001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,472,832
App. No.
16/449,131
Granted
Oct 18, 2022
Kind
B2
Abstract

Provided herein are synthetic analogs of withanolide natural products and their pharmaceutical uses in treating neurodegenerative diseases.

Claims (18)

1. A method of treating amyotrophic lateral sclerosis in a patient comprising administering to the patient a therapeutically effective amount of a compound Formula (Ia):

wherein:

R 1 is hydrogen, or methyl; and

R 3 is hydrogen, or methyl,

wherein, R 1 and R 3 cannot both be hydrogen.

2. The method of claim 1 , wherein R 1 is methyl and R 3 is hydrogen.

3. The method of claim 1 , wherein R 1 is hydrogen and R 3 is methyl.

4. The method of claim 1 , wherein R 1 is methyl and R 3 is methyl.

5. A method of administering a compound to a patient, comprising: administering to the patient a compound Formula (Ia):

wherein:

R1 is hydrogen, or methyl; and

R3 is hydrogen, or methyl,

wherein, R1 and R3 cannot both be hydrogen,

wherein the patient is identified as having a disease characterized by a TDP-43 proteinopathy selected from the group consisting of: amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and frontotemporal lobar degeneration.

6. The method of claim 5 , wherein R 1 is methyl and R 3 is hydrogen.

7. The method of claim 5 , wherein R 1 is hydrogen and R 3 is methyl.

8. The method of claim 5 , wherein R 1 is methyl and R 3 is methyl.

9. The method of claim 5 , wherein the patient is identified as having amyotrophic lateral sclerosis.

Assignments (1)
CHANGE OF NAME Recorded Sep 2, 2022
From: IMSTAR THERAPEUTICS INC.
To: ARNA THERAPEUTICS INC.
Reel/Frame 060981/0487 →
Continuity (4)
Division 15038927
Provisional Application 61908455 · Nov 25, 2013
Related Publication 20190315798A1 · Oct 17, 2019
Related Publication 20200325168A9 · Oct 15, 2020